Olsalazine: Difference between revisions
m Protected "Olsalazine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| Line 1: | Line 1: | ||
==Overview== | ==Overview== | ||
| Line 50: | Line 50: | ||
{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}} | {{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}} | ||
[[Category:Non-steroidal anti-inflammatory drugs]] | [[Category:Non-steroidal anti-inflammatory drugs]] | ||
Revision as of 14:29, 20 August 2012
Overview
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 99% |
| Elimination half-life | 0.9 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C14H10N2O6 |
| Molar mass | 302.239g/mol |
|
WikiDoc Resources for Olsalazine |
|
Articles |
|---|
|
Most recent articles on Olsalazine |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Olsalazine at Clinical Trials.gov Clinical Trials on Olsalazine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Olsalazine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Olsalazine Discussion groups on Olsalazine Patient Handouts on Olsalazine Directions to Hospitals Treating Olsalazine Risk calculators and risk factors for Olsalazine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Olsalazine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. It is sold under the name Dipentum.
The chemical name is 3,3' -azobis (6-hydroxybenzoate)salicylic acid. It is sold as the disodium salt.
Like Balsalazide, Olsalazine is believed to deliver Mesalazine, or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is that active site of disease in ulcerative colitis.
History
Olsalazine gained Food and Drug Administration (FDA) approval in 1990.
Supply
The drug is supplied by UCB Pharma.
Other indications
The Australian biotech company Giaconda has developed a combination therapy for treat constipation-predominant Irritable Bowel Syndrome that uses olsalazine and the anti-gout drug colchicine.
External links
Template:Antidiarrheals, intestinal anti-inflammatory/anti-infective agents
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Non-steroidal anti-inflammatory drugs
- Gastroenterology
- Drugs